Log In
Print
BCIQ
Print
Print this Print this
 

Corifact

  Manage Alerts
Collapse Summary General Information
Company CSL Ltd.
DescriptionHuman coagulation factor XIII concentrate
Molecular Target Not applicable
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationFactor XIII deficiency
Indication DetailsPrevent bleeding in patients with congenital Factor XIII deficiency; Treat peri-operative surgical bleeding in adult and pediatric patients with congenital factor XIII (FXIII) deficiency
Regulatory Designation

U.S. - Accelerated Approval (Prevent bleeding in patients with congenital Factor XIII deficiency)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today